Biomarker Testing: Piercing the Fog of Alzheimer’s and Related Dementia
Alzheimer’s disease (AD) and related dementia is one of the growing threats to the sustainability of health and care systems in developed countries, and efforts to find therapies have had scant success. The main reasons for this are lack of efficient therapy, which is linked to too late discovery of...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Karger Publishers
2020-11-01
|
| Series: | Biomedicine Hub |
| Subjects: | |
| Online Access: | https://www.karger.com/Article/FullText/511233 |
| _version_ | 1831587897828966400 |
|---|---|
| author | Denis Horgan Flavio Nobili Charlotte Teunissen Timo Grimmer Dinko Mitrecic Laurence Ris Zvezdan Pirtosek Chiara Bernini Antonio Federico Daniel Blackburn Giancarlo Logroscino Nikos Scarmeas |
| author_facet | Denis Horgan Flavio Nobili Charlotte Teunissen Timo Grimmer Dinko Mitrecic Laurence Ris Zvezdan Pirtosek Chiara Bernini Antonio Federico Daniel Blackburn Giancarlo Logroscino Nikos Scarmeas |
| author_sort | Denis Horgan |
| collection | DOAJ |
| description | Alzheimer’s disease (AD) and related dementia is one of the growing threats to the sustainability of health and care systems in developed countries, and efforts to find therapies have had scant success. The main reasons for this are lack of efficient therapy, which is linked to too late discovery of the disease itself. With this in mind, biomarkers are recognised as an element which can bring a major contribution to research, helping elucidate the disease and the search for treatments. They are also playing an increasing role in early detection and timely diagnosis, which are considered the principal hopes of effective management in the absence of an effective drug. The current arsenal of biomarkers could already, if more widely deployed, provide an effective minimum service to patients and health systems. A concerted action by policy makers and stakeholders could drive progress in access to AD biomarker testing to provide an optimum service in the medium term. This paper discusses how to improve the use of and access to biomarker testing in the detection and diagnosis of AD and other diseases featuring dementia, and how EU healthcare systems could benefit. It outlines the challenges, lists the achievements to date, and highlights the actions needed to allow biomarker testing to deliver more fully on their potential in AD. |
| first_indexed | 2024-12-17T22:04:11Z |
| format | Article |
| id | doaj.art-2e04db777455481cb93a6a4fea6d5e24 |
| institution | Directory Open Access Journal |
| issn | 2296-6870 |
| language | English |
| last_indexed | 2024-12-17T22:04:11Z |
| publishDate | 2020-11-01 |
| publisher | Karger Publishers |
| record_format | Article |
| series | Biomedicine Hub |
| spelling | doaj.art-2e04db777455481cb93a6a4fea6d5e242022-12-21T21:30:54ZengKarger PublishersBiomedicine Hub2296-68702020-11-01538410510.1159/000511233511233Biomarker Testing: Piercing the Fog of Alzheimer’s and Related DementiaDenis HorganFlavio NobiliCharlotte TeunissenTimo GrimmerDinko MitrecicLaurence RisZvezdan PirtosekChiara BerniniAntonio FedericoDaniel BlackburnGiancarlo LogroscinoNikos ScarmeasAlzheimer’s disease (AD) and related dementia is one of the growing threats to the sustainability of health and care systems in developed countries, and efforts to find therapies have had scant success. The main reasons for this are lack of efficient therapy, which is linked to too late discovery of the disease itself. With this in mind, biomarkers are recognised as an element which can bring a major contribution to research, helping elucidate the disease and the search for treatments. They are also playing an increasing role in early detection and timely diagnosis, which are considered the principal hopes of effective management in the absence of an effective drug. The current arsenal of biomarkers could already, if more widely deployed, provide an effective minimum service to patients and health systems. A concerted action by policy makers and stakeholders could drive progress in access to AD biomarker testing to provide an optimum service in the medium term. This paper discusses how to improve the use of and access to biomarker testing in the detection and diagnosis of AD and other diseases featuring dementia, and how EU healthcare systems could benefit. It outlines the challenges, lists the achievements to date, and highlights the actions needed to allow biomarker testing to deliver more fully on their potential in AD.https://www.karger.com/Article/FullText/511233alzheimer’s diseasebiomarkersdiagnosis |
| spellingShingle | Denis Horgan Flavio Nobili Charlotte Teunissen Timo Grimmer Dinko Mitrecic Laurence Ris Zvezdan Pirtosek Chiara Bernini Antonio Federico Daniel Blackburn Giancarlo Logroscino Nikos Scarmeas Biomarker Testing: Piercing the Fog of Alzheimer’s and Related Dementia Biomedicine Hub alzheimer’s disease biomarkers diagnosis |
| title | Biomarker Testing: Piercing the Fog of Alzheimer’s and Related Dementia |
| title_full | Biomarker Testing: Piercing the Fog of Alzheimer’s and Related Dementia |
| title_fullStr | Biomarker Testing: Piercing the Fog of Alzheimer’s and Related Dementia |
| title_full_unstemmed | Biomarker Testing: Piercing the Fog of Alzheimer’s and Related Dementia |
| title_short | Biomarker Testing: Piercing the Fog of Alzheimer’s and Related Dementia |
| title_sort | biomarker testing piercing the fog of alzheimer s and related dementia |
| topic | alzheimer’s disease biomarkers diagnosis |
| url | https://www.karger.com/Article/FullText/511233 |
| work_keys_str_mv | AT denishorgan biomarkertestingpiercingthefogofalzheimersandrelateddementia AT flavionobili biomarkertestingpiercingthefogofalzheimersandrelateddementia AT charlotteteunissen biomarkertestingpiercingthefogofalzheimersandrelateddementia AT timogrimmer biomarkertestingpiercingthefogofalzheimersandrelateddementia AT dinkomitrecic biomarkertestingpiercingthefogofalzheimersandrelateddementia AT laurenceris biomarkertestingpiercingthefogofalzheimersandrelateddementia AT zvezdanpirtosek biomarkertestingpiercingthefogofalzheimersandrelateddementia AT chiarabernini biomarkertestingpiercingthefogofalzheimersandrelateddementia AT antoniofederico biomarkertestingpiercingthefogofalzheimersandrelateddementia AT danielblackburn biomarkertestingpiercingthefogofalzheimersandrelateddementia AT giancarlologroscino biomarkertestingpiercingthefogofalzheimersandrelateddementia AT nikosscarmeas biomarkertestingpiercingthefogofalzheimersandrelateddementia |